News & Views

  • Collaboration to Evaluate Processes for Scalable AAV Platform
    Prof. Daniel Smith

Collaboration to Evaluate Processes for Scalable AAV Platform

Oct 19 2018 Read 329 Times

The Centre for Process Innovation, international contract development and manufacturing organisation (CDMO) Cobra Biologics and GE Healthcare Life Sciences have established a three-way partnership, with aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments. The partnership, funded by a £570K Innovate UK grant, will focus on the use of GE Healthcare’s Puridify fibre-based chromatography technology platform to achieve high purification productivity of protein biopharmaceuticals. CPI and Cobra Biologics will help demonstrate the application of the purification platform to gene therapy, leading to the development of a multistep fibre-based chromatography purification process for AAV. These viral vectors will be produced in-house by Cobra Biologics and CPI using a system developed via an ongoing Innovate UK grant. The developed fibre-based technology will then be transferred to CPI, where entire process flowsheets incorporating the technology will be run to demonstrate suitability for AAV manufacture.

Honorary Industry Professor Daniel Smith, Chief Scientific Officer at Cobra Biologics, said: “The scalable chromatographic purification of recombinant AAV-based viral vectors for use in gene therapy applications remains an area of intense global development, essential to support the rapidly increasing market opportunity for these innovative medicines. As such, Cobra Biologics is pleased to be collaborating with both GE Healthcare Life Sciences and CPI as part of this Innovate UK funded project. The application and implementation of the fibre-based chromatography for the purification of AAV vectors could provide a step change in the technology available, allowing for the scalable, cost effective production of this emerging class of innovative medicines.”

Read comments0

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.


Digital Edition

Lab Asia February 2019

February 2019

In this edition Articles - Detection of molecular markers in aquatic sediments by ion profi les obtained by GC/MS system - Fighting the Resistance: How Rapid Microbial ID with MALDI MS and A...

View all digital editions

Events

BioPharma World Expo 2019

Feb 20 2019 Mumbai, India

Medical Fair India 2019

Feb 21 2019 New Delhi, India

Biotech World

Feb 25 2019 Moscow, Russia

China Lab 2019

Feb 26 2019 Guangzhou, China

SmartLab Exchange

Feb 27 2019 Berlin, Germany

View all events